ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1498

Both Race and Socioeconomic Status Affect Mortality in SLE

Gursimran Kaur1, Daniel Goldman2, Andrea Fava3, Laurence Magder4 and Michelle Petri2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Timonium, MD, 3Johns Hopkins University, Baltimore, MD, 4University of Maryland, Baltimore, Baltimore, MD

Meeting: ACR Convergence 2025

Keywords: Demographics, Mortality, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: A recent meta-analysis found an overall 2.87-fold increase in all-cause mortality in systemic lupus erythematosus (SLE) with cause-specific increases in renal disease, infections, cardiovascular disease, stroke and cancer. An increase in mortality due to lupus nephritis was found between 2015-2020. Yen et al examined SLE mortality in the United States from 1968 to 2013. Multiple logistic regression found sex (male), race (blacks) and region (the South) were associated with SLE mortality. We evaluated the role of different demographic variables on mortality outcomes in systemic lupus erythematosus (SLE) in a large single-center cohort.

Methods: Using data from the cohort and the National Death Index, we analyzed demographic and clinical information to discover links between demographic characteristics and mortality. Cox proportional hazards models were used to assess the independent effects of age, gender, race/ethnicity, education and socioeconomic status on mortality risk while controlling for disease activity and comorbidities. Given the strong non-linear relationship between age and mortality, all estimated associations with mortality are adjusted for age at diagnosis and age at diagnosis squared.

Results: Of the 3,021 patients included from the cohort, 628 deaths were recorded. They were 89% female, 34% had a household income of more than $40,000, and 82% had 12 years or more years of education. They were 48% White, 50% Black, 1% East Asian and 1% Other or mixed racial background. Male gender (p=0.0098), Black race vs White (p < 0.0001), less than 12 years of education (p < 0.0001), and household income of less than or equal to $40,000 (p < 0.0001) were associated with increased mortality in both univariate (Table 1) and multivariable (Table 2) models. Decreased mortality was observed for those diagnosed with lupus after 1990 (Table 1, Table 2). White race with high income had the lowest mortality, and black race with low income had the highest mortality (Figure 1).

Conclusion: Patel et al, in a meta-analysis, found that Blacks had higher mortality than Whites, but could not comment on socioeconomic factors. In the Eight Americas study, Falasinnu et al found that Blacks sharing the same social and geographic contexts as Whites had higher mortality, but SLE mortality did not vary between socially advantaged and disadvantaged Blacks. Our results, using individual patient data to measure socioeconomic status in 2 ways (household income and education) clearly contradict the Eight Americas study. Race and socioeconomic status both played a role in mortality risk in SLE, even in a single center of excellence (where access to care and medication were not issues). Our single center study was able to use actual individual patient household income and education, and not infer it from zip codes or county of residence. Black race with high income had better survival than white race with low income.

Supporting image 1Table 1. Predictors of Mortality based on a Cox Proportional Hazard Model

Supporting image 2Table 2. Multivariable Model of Predictors of Mortality

Supporting image 3Figure 1. Estimated probability of survival by years since diagnosis by Race and Income


Disclosures: G. Kaur: None; D. Goldman: None; A. Fava: Artiva, 2, AstraZeneca, 1, 2, Bain Capital, 2, Biogen, 1, Bristol-Myers Squibb(BMS), 2, Exagen, 5, 9, Quotient Therapeutics, 2, UCB, 6, Zenas, 2; L. Magder: None; M. Petri: Amgen, 2, AnaptysBio, 2, Annexon Bio, 2, AstraZeneca, 2, 5, Atara Biosciences, 2, Aurinia, 2, 5, Autolus, 2, Bain Capital, 2, Baobab Therapeutics, 2, Biocryst, 2, Biogen, 2, Boxer Capital, 2, Cabaletto Bio, 2, Caribou Biosciences, 2, CTI Clinical Trial and Consulting Services, 2, CVS Health, 2, Dualitybio, 2, Eli Lilly, 2, 5, EMD Serono, 2, Emergent, 2, Escient Pharmaceuticals, 2, Exagen, 5, Exo Therapeutics, 2, Gentibio, 2, GlaxoSmithKlein(GSK), 2, 5, iCell Gene Therapeutics, 2, Innovaderm Research, 2, IQVIA, 2, Janssen, 5, Kezar Life Sciences, 2, Kira Pharmaceuticals, 2, Nexstone Immunology, 2, Nimbus Lakshmi, 2, Novartis, 2, Ono Pharma, 2, PPD Development, 2, Proviant, 2, Regeneron, 2, Seismic Therapeutic, 2, Senti Biosciences, 2, Sinomab Biosciences, 2, Steritas, 2, Takeda, 2, Tenet Medicines, 2, TG Therapeutics, 2, UCB, 2, Variant Bio, 2, Worldwide Clinical Trials, 2, Zydus, 2.

To cite this abstract in AMA style:

Kaur G, Goldman D, Fava A, Magder L, Petri M. Both Race and Socioeconomic Status Affect Mortality in SLE [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/both-race-and-socioeconomic-status-affect-mortality-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/both-race-and-socioeconomic-status-affect-mortality-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology